Pharmacology of polymyxins: new insights into an 'old' class of antibiotics
Tony Velkov, Kade D Roberts, Roger L Nation, Philip E Thompson, Jian Li
FUTURE MICROBIOLOGY | FUTURE MEDICINE LTD | Published : 2013
Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global medical challenge. No new antibiotics will be available for these 'superbugs' in the near future due to the dry antibiotic discovery pipeline. Colistin and polymyxin B are increasingly used as the last-line therapeutic options for treatment of infections caused by multidrug-resistant Gram-negative bacteria. This article surveys the significant progress over the last decade in understanding polymyxin chemistry, mechanisms of antibacterial activity and resistance, structure-activity relationships and pharmacokinetics/pharmacody..View full abstract
Awarded by National Institute of Allergy and Infectious Diseases (NIH)
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The authors are supported by Award Numbers R01AI098771 (all authors), R01AI079330 and R01AI070896 (RL Nation and J Li) from the National Institute of Allergy and Infectious Diseases (NIH). J Li is an Australian National Health and Medical Research Council Senior Research Fellow and T Velkov is an Australian National Health and Medical Research Council Industry Career Development Award Fellow. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.